Multivariate time-to-event analysis of multiple adverse events of drugs in integrated analyses

Statistics in Medicine

Volumn 26, Issue 7, 2007, Pages 1518-1531

  Güttner, Achim ^a   Kübler, Jürgen ^a   Pigeot, Iris ^b,c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF BREMEN   (Germany)

^c LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

Author keywords

Adverse events; Multivariate cox regression; Stratification

Indexed keywords

CHOLINESTERASE INHIBITOR; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; BRONCHITIS; CHILL; CLINICAL RESEARCH; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG SAFETY; DYSPNEA; FEVER; HEADACHE; HUMAN; INFLUENZA; MAXIMUM LIKELIHOOD METHOD; MULTIVARIATE ANALYSIS; NULL HYPOTHESIS; PHARYNGITIS; PNEUMONIA; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; STATISTICAL DISTRIBUTION; STATISTICAL PARAMETERS; SURVIVAL TIME; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; COMMON COLD; HUMANS; META-ANALYSIS; MULTIVARIATE ANALYSIS; PHARMACEUTICAL PREPARATIONS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS;

EID: 33947185734     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2637     Document Type: Article

References (25)

1. ICH E2A. Clinical safety data management: definitions and standards for expedited reporting. Federal Register 1995; 60:11284-11287.
2. ICH E3. Structure and content of clinical study reports. Federal Register 1996; 61:37320-37343.
3. ICH E9. Statistical principles for clinical trials. Federal Register 1998; 63:49583-49598.
4. McEntegart DJ. Pooling in integrated safety databases. Drug Information Journal 2000; 34:495-499.
5. Chuang-Stein Ch. Safety analysis in controlled clinical trials. Drug Information Journal 1998; 32:1363S-1372S.
6. O'Neill RT. Statistical analyses of adverse event data from clinical trials, special emphasis on serious events. Drug Information Journal 1987; 21:9-20.
7. O'Neill RT. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues on international harmonisation. Statistics in Medicine 1995; 14:1117-1127.
8. Dubin JA, Müller HG, Wang JL. Event history graphs for censored survival data. Statistics in Medicine 2001; 20:2951-2964.
9. Enas GG, Goldstein DJ. Defining, monitoring and combining safety information in clinical trials. Statistics in Medicine 1995; 14:1099-1111.
10. Wei U, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modelling marginal distributions. Journal of the American Statistical Association 1989; 84:1065-1073.
11. Spiekerman CF, Lin DY. Marginal regression models for multivariate failure time data. Journal of the American Statistical Association 1998; 93:1164-1175.
12. Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. Journal of the American Statistical Association 1992; 87:942-951.
13. Gray RJ. Spline-based tests in survival analysis. Biometrics 1994; 50:640-652.
14. Berhane K, Weissfeld LA. Inference in spline-based models for multiple time-to-event data, with applications to a breast cancer prevention trial. Biometrics 2003; 59:859-868.
15. Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Statistics in Medicine 1994; 13:2233-2247.
16. Cox DR. Partial likelihood. Biometrika 1975; 62:269-276.
17. Cai J. Hypothesis testing of hazard ratio parameters in marginal models for multivariate failure time data. Lifetime Data Analysis 1999; 5:39-53.
18. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B, Metrifonate Study Group. Metrifonte treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998; 50:1214-1221.
19. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B. Metrifonte benefits cognitive, behavioral and global function in Alzheimer's disease patients. Neurology 1998; 50:1222-1230.
20. Dubois B, McKeith I, Orgogozo J-M, Collins O, Meulien D, MALT Study Group. A multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy, tolerability, and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. International Journal of Geriatric Psychiatry 1999; 14:973-982.
21. Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry 1999; 60:318-325.
22. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Annals of Statistics 1982; 10:1100-1120.
23. Cai J, Prentice RL. Estimating equations for hazard ratio parameters based on correlated failure time data. Biometrika 1995; 82:151-164.
24. Hougaard P. Analysis of Multivariate Survival Data. Springer: New York, 2000.
25. Spiekerman CF, Lin DY. Checking the marginal Cox model for correlated failure time data. Biometrika 1996; 83:143-156.